Compare · A vs TXG
A vs TXG
Side-by-side comparison of Agilent Technologies Inc. (A) and 10x Genomics Inc. (TXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and TXG operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A is the larger of the two at $49.49B, about 5.2x TXG ($9.43B).
- Over the past year, A is up 20.9% and TXG is up 431.5% - TXG leads by 410.6 points.
- TXG has been more active in the news (6 items in the past 4 weeks vs 3 for A).
- Both have 25 recent analyst ratings on file.
- Company
- Agilent Technologies Inc.
- 10x Genomics Inc.
- Price
- $172.97-1.42%
- $69.87-3.47%
- Market cap
- $49.49B
- $9.43B
- 1M return
- +10.66%
- -9.24%
- 1Y return
- +20.92%
- +431.53%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- 2019
- News (4w)
- 3
- 6
- Recent ratings
- 25
- 25
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Latest A
- Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence
- Agilent Introduces the NovoStation Sample Preparation System for Automated Flow Cytometry Workflows
- Agilent Introduces Gen5 AI Cell Identification Module for BioTek Automated Cell Imagers
- SEC Form EFFECT filed by Agilent Technologies Inc.
- SEC Form 424B3 filed by Agilent Technologies Inc.
- Agilent Launches TapeStationDx Systems for Clinical NGS Sample Quality Control
- CORRECTING and REPLACING Agilent Announces Cash Dividend of 25.5 Cents per Share
- Agilent Announces Cash Dividend of 25.5 Cents per Share
- Agilent to Participate in J.P. Morgan U.S. All Stars Conference
- Director Boehnlein Glenn S was granted 817 shares (SEC Form 4)
Latest TXG
- 10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.
- 10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers
- 10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions
- 10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands
- Argus initiated coverage on 10x Genomics with a new price target
- Director Suliman Shehnaaz sold $464,668 worth of shares (5,723 units at $81.19) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 23,792 units (SEC Form 4)
- Chief Executive Officer Saxonov Serge sold $2,030,562 worth of shares (25,000 units at $81.22) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,050,249 units (SEC Form 4)
- SEC Form 144 filed by 10x Genomics Inc.
- Chief Financial Officer Taich Adam sold $2,995,470 worth of shares (46,388 units at $64.57) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 316,344 units (SEC Form 4)